There is a paucity of data on the prevalence of multifocal primary hyperhidrosis and changes in hyperhidrosis severity over time.
The goal of this study was to better understand multifocal primary hyperhidrosis, prevalence and distribution of hyperhidrosis by focal site, age of onset of symptoms by focal area, and change in hyperhidrosis severity over time and with seasons.
The International Hyperhidrosis Society, through an unrestricted research grant from Revance Therapeutics, conducted an online survey of registered visitors to its Web site. Participants identified as having “excessive sweating” and opted to participate in the survey (23 questions) after an e-mail invitation.
The survey data illustrate that multifocal primary hyperhidrosis is more common than previously believed and that multifocal hyperhidrosis is more common than singular focal hyperhidrosis (81% of patients reported 3 or more focal hyperhidrotic sites). The data also show that sweating symptom severity does not improve with age but stays the same or gets worse and is “bothersome” throughout the year.
Recognition of the chronic and multifocal nature of primary hyperhidrosis is useful for treating hyperhidrosis patients long term and illustrates a need for treatments or treatment combinations that are effective for multiple body areas.
*Department of Dermatology, St. Louis University School of Medicine, St. Louis, Missouri;
†International Hyperhidrosis Society, Charleston, South Carolina;
‡Candesant Biomedical, Palo Alto, California;
§Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia
Address correspondence and reprint requests to: Lisa J. Pieretti, MBA, International Hyperhidrosis Society, 1260 Smythe Street, Charleston, SC 29492, or e-mail: firstname.lastname@example.org
Revance Therapeutics provided an unrestricted research grant to the International Hyperhidrosis Society. Revance Therapeutics is developing a topical botulinum toxin for the treatment of hyperhidrosis.
A.M. Ballard is a consultant for the International Hyperhidrosis Society. N.L. Hunt is a former consultant for Revance Therapeutics, Newark, CA. L.J. Pieretti is executive director for the International Hyperhidrosis Society. The remaining authors have indicated no significant interest with commercial supporters.